Press Release: Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myeloma
Sarclisa recommended for EU approval by the CHMP to treat transplant-ineligible newly diagnosed multiple myelomaRecommendation based on IMROZ ...
pharmaphorum1d
Sanofi wins appeal in spat with NICE over Sarclisa
The drugmaker has won an appeal against NICE's recent final draft guidance on Sarclisa (isatuximab) as a regimen alongside ...
The Pharma Letter2d
UK looks again at Sarclisa for myeloma as demand grows
Sanofi (Euronext: SAN) has announced that the UK's health technology assessor will conduct a new review of its Sarclisa ...
pharmaphorum4d
J&J bids to add smouldering myeloma to Darzalex label
The marketing applications with the EMA and FDA are for J&J and partner Genmab's Darzalex Faspro version of the anti-CD38 ...
Targeted Oncology6d
Quadruplets Seen as Top Option in Transplant-Ineligible Multiple Myeloma Due to Efficacy
Samer A. Al'Hadidi, MD, MS, discusses the response and survival of 2 quadruplet therapy trials for patients with ...
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update
Sanofi is conducting the two-part multicenter, randomized, open-label, controlled, parallel-group study (NCT04643002) to evaluate the safety, efficacy, pharmacokinetics and biomarker data of ...
The American Journal of Managed Care22d
MRD: A Game Changer in Multiple Myeloma
Also make sure to check our part 1 of our exclusive interview with her regarding the recent FDA approval of isatuximab (Sarclisa; Sanofi-Aventis) plus bortezomib (Velcade; Takeda), lenalidomide ...